The partnership will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients. The two companies aim to develop an industry-first digital platform, using advanced analytics to provide workflow solutions and apps that support clinical decisions. This will allow the seamless integration and analysis of in-vivo and in-vitro data, patient records, medical best practice, real time monitoring and the latest research outcomes. Clinicians will then have the comprehensive decision support for providing the right treatment and quality of care for their patients.įor example, oncology care teams with multiple specialists will have a comprehensive data dashboard to review, collaborate and align on treatment decisions for cancer patients at each stage of their disease. In the critical care setting, data from a patient’s hospital monitoring equipment will be integrated with their biomarker, tissue pathology, genomic and sequencing data, helping physicians to identify, or even predict severe complications before they strike. GE Healthcare is a worldwide leader in medical imaging equipment, while Roche Diagnostics is the global leader in in-vitro diagnostics. “This is the first time that two major players in healthcare have combined advanced analytics with in-vivo and in-vitro diagnostics to this degree. We believe this alliance will help accelerate the delivery of data-driven precision health for customers, patients and the healthcare industry,” said Kieran Murphy, President & CEO of GE Healthcare. “This unique partnership will deliver innovative solutions and insights in clinical decision-making. Our goal is to support clinicians and other relevant stakeholders for the benefit of patients by providing the right decision support at the right time and through comprehensive digital offerings,” said Roland Diggelmann, CEO Roche Diagnostics. Harnessing data and analytics across hardware, software and biotech, GE Healthcare is the $18 billion healthcare business of GE (NYSE: GE). Visit us at or follow us on Facebook, LinkedIn, Twitter and The Pulse for latest news As a leading provider of medical imaging equipment, with a track record of more than 100 years in the industry and more than 50,000 employees across 100 countries, we transform healthcare by delivering better outcomes for providers and patients. I suppose that's why it's so important that we're here.Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Yanaril: The Wilderqueen, eh? Times are changing in Valenwood, aren't they?Īll this has put the Dominion in a delicate position. Is it true then? Did you persuade the Wilderking to swear loyalty to Queen Ayrenn? When will I learn not to wager my gold against Razum-dar's instincts? I will open a portal to the western gate of Greenheart. I know not where they've taken it, but you should search in Woodhearth, to the west. As you may know, they stole the Staff of Magnus. I only hope Ayrenn realizes that her best ally stands before me now.īefore Aranias' memories fade though, there is something else I must tell you. On behalf of myself and the Valenwood, you have our allegiance. Queen Ayrenn sent me to ask your allegiance on her behalf. Would you still make such a request to me now? Wilderqueen: I know why you originally came here-to ask for the Wilderking's allegiance to the Aldmeri Dominion-to know the Valenwood was on your side. I should travel to Woodhearth and investigate to see if theres been any Veiled Heritance activity there. She suggested I go to the city of Woodhearth. Required Level: 26 Reward: Text of the Quest:īefore losing Aranias memories, the Wilderqueen told me that she knew about the Veiled Heritance plot to steal the Staff of Magnus.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |